The Biology of Obesity and Metabolic Syndrome

The World Health Organization (WHO) now describes obesity as a chronic disease that results from complex interactions between environmental and psychosocial influences and biological susceptibility. By its 2024 figures, 940 million adults had obesity, about 16 percent of adults worldwide. The old story, that it is simply eating too much and moving too little, leaves out the hormones, brain circuits, and food environment that decide how much a person eats and how the body responds when weight changes. This article walks through that biology, from fat tissue to metabolic syndrome, and what the best trials show about treatment.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research, but every person's situation differs.

Why researchers call obesity a disease, and what that does and does not mean

Obesity is defined for adults as a body mass index (BMI) of 30 or more, where BMI is weight in kilograms divided by height in meters squared. WHO's 2026 fact sheet puts the number of people living with obesity at about 1.1 billion, roughly 1 in 7 people, and attributes an estimated 3.7 million deaths in 2023 to a higher-than-optimal BMI.

Calling it a chronic disease is a statement about mechanism, not blame. A disease in this sense has a pathophysiology (a biological process that has gone off track), predictable complications, and treatments that work better when they address that process. The causes WHO lists include obesogenic environments, neurobiological and metabolic dysregulation, and genetic variation. Those three do not act separately. A person with genes that make appetite louder lives in a world with cheap, calorie-dense food available around the clock, and their brain does the rest.

BMI itself is a blunt instrument. It cannot tell muscle from fat or reveal where fat sits, which turns out to matter a great deal, as later sections show. It remains useful for population statistics. For the individual, doctors increasingly pair it with waist measurements and blood tests.

For the global distribution of the problem, see the ranking in countries with the highest obesity rates. Here the focus is the machinery inside the body.

Fat tissue is an endocrine organ, not a storage shed

Most people picture body fat as padding, an inert depot that holds spare energy. Adipose tissue is better thought of as a gland that happens to be spread across the body. It releases signaling molecules called adipokines that influence appetite, immune activity, blood vessels, and how other tissues respond to insulin. (For a grounding in how hormones pass messages through blood, see how hormones work in the endocrine system.)

Four players matter most.

• Leptin is made in proportion to fat mass and tells the brain how much energy is stored. It was identified in mice in 1994 by Jeffrey Friedman's group (Zhang and colleagues) as the product of the gene that is defective in the ob/ob obese mouse.
• Adiponectin helps tissues respond to insulin and has anti-inflammatory effects. It behaves in the opposite direction to most adipokines: levels tend to fall as fat mass rises, which removes a protective signal at the wrong moment.
• Inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) are released by fat tissue, especially visceral fat, and by immune cells that move into it. Together they produce a low-grade, body-wide inflammatory tone.
• Resistin has been linked to insulin resistance in rodents. Its role in people is less clear, so it is best treated as a candidate rather than a settled driver.

An analogy: fat tissue works like a thermostat sensor and a radio transmitter in one. It senses how much energy is stored and broadcasts that fact, and when it becomes overloaded the broadcast turns noisy. The messages become distorted, and organs downstream respond to the noise.

The brain's body-weight thermostat

The hypothalamus, a small structure deep in the brain, is where the signals from fat, gut, and blood are weighed against each other. Researchers sometimes call the whole feedback system the adipostat, by analogy with a thermostat that defends a temperature.

In the arcuate nucleus of the hypothalamus, two groups of neurons act like a pair of opposing pedals. One group, which makes the signaling molecules NPY and AgRP, pushes appetite up and metabolic rate down. The other group, which makes POMC and CART, pushes appetite down. Leptin reaching these cells inhibits the first group and activates the second, so a rising fat store should quiet hunger.

The strongest evidence that this circuit matters in people comes from rare genetic cases. In 1997, researchers described two severely obese cousins in a family with a mutation that prevented leptin production. In 1999, Farooqi and colleagues reported that a child with congenital leptin deficiency, who had marked hyperphagia (constant hunger), improved markedly in appetite and body fat after a year of recombinant leptin treatment. Leptin replacement is therefore a real treatment, but only for people who lack the hormone, and congenital deficiency is rare.

Leptin resistance: a broadcast the brain stops hearing

Most people with obesity have the opposite problem from those rare patients. Their leptin levels are high, because they have more fat, yet hunger persists. This pattern is called leptin resistance. Proposed mechanisms include inflammation in the hypothalamus, reduced transport of leptin across the blood-brain barrier, and weakened signaling inside the target neurons. The details are still debated, and leptin resistance is better understood as a description of what is observed than as a fully mapped mechanism.

An everyday comparison: the smoke alarm that keeps ringing until you stop noticing it. A signal that is always on loses its ability to persuade. The practical consequence is that the brain can behave as though stores are low even when they are ample, so it holds on to weight and turns up appetite.

Why weight defends itself

Set-point theory proposes that the brain defends a range of body weight. The mid-twentieth-century Minnesota Starvation Experiment, led by Ancel Keys, showed in healthy volunteers that when food is restricted, the body responds with intense hunger, a slower metabolism, and preoccupation with food. Modern work shows similar pushback after intentional weight loss.

The best-known quantitative example is the follow-up to the television competition The Biggest Loser. Fothergill and colleagues measured 14 contestants at baseline, at the end of the 30-week competition, and six years later. Resting metabolic rate fell by about 610 kilocalories per day by the end of the show. Six years on, contestants had regained about 41 kg of the weight they had lost, and their resting metabolic rate was still about 704 kilocalories per day below baseline. After adjusting for body composition and age, the "metabolic adaptation" was about minus 499 kilocalories per day.

Two cautions apply. The group was small and unusual, and a later reanalysis by Kevin Hall suggested that the contestants' very large increases in physical activity may have contributed to the compensatory drop in resting metabolic rate. The finding is real, but it should not be read as a fixed law for all dieters. The more careful summary is that the body tends to resist weight change, and that the resistance can persist.

The food environment works on the same circuits

Energy balance is true as accounting, since weight change reflects energy in versus energy out over time. As advice, it fails to explain why intake shifts in the first place. A controlled experiment run at the US National Institutes of Health gives a clear example.

In 2019, Kevin Hall and colleagues admitted 20 adults to a metabolic ward for a crossover study, with each person spending two weeks on an ultra-processed diet and two weeks on a minimally processed diet. The meals were matched for calories offered, sugars, fiber, fat, and carbohydrates, and participants could eat as much as they wanted. On the ultra-processed diet they ate about 508 kilocalories per day more, gained an average of about 0.9 kg, and put on about 0.4 kg of body fat. The group was small, the setting was artificial, and the study lasted only a few weeks, so it shows a mechanism rather than long-term outcomes. Still, it is a direct demonstration that the composition of food can change intake when other nutrients are held constant.

The practical meaning is that appetite is not a pure act of will. Highly palatable, easy-to-eat foods engage reward and satiety circuits, and the effect is measurable. For a related look at one nutrient that often gets blamed, see is sugar really that bad for you.

Other inputs: sleep, stress, and the gut

Appetite circuits also respond to inputs that have little to do with food. Short sleep alters hunger-related hormones in experimental studies, and the body clock influences when and how glucose is handled; see circadian rhythm and your body's internal clock and the science of sleep and what happens without it. Chronic psychological stress activates the cortisol system, which promotes fat deposition around the abdomen in some people; the hormone's role is explored in cortisol and the stress response.

The gut microbiome is a further contributor. In a widely cited 2006 Nature study, Turnbaugh and colleagues found that germ-free mice given microbes from obese mice gained more fat than those given microbes from lean mice, on the same diet. That demonstrates that microbes can influence energy harvest in a mouse. Translating it to people is harder. Human studies of microbiome differences in obesity are inconsistent, and whether the changes cause obesity or follow from diet and weight is still being worked out. For background, see the gut microbiome explained and the human microbiome and gut-brain axis.

What metabolic syndrome is

Metabolic syndrome is not a single illness. It is a cluster of findings that together signal a high risk of type 2 diabetes and cardiovascular disease. The National Heart, Lung, and Blood Institute says a person may have it with three or more of five conditions: a large waistline, high blood pressure, high blood sugar, high triglycerides, and low HDL ("good") cholesterol. One widely used version of the criteria is from the National Cholesterol Education Program's Adult Treatment Panel III (ATP III):

Component	ATP III threshold
Waist circumference	Above 102 cm (40 in) in men, above 88 cm (35 in) in women
Triglycerides	150 mg/dL or higher, or on treatment
HDL cholesterol	Below 40 mg/dL in men, below 50 mg/dL in women
Blood pressure	130/85 mmHg or higher, or on treatment
Fasting glucose	100 mg/dL or higher, or on treatment

Different organizations have set slightly different cutoffs, particularly for waist size in different ethnic groups, so the numbers above describe one standard rather than a universal rule.

How common is it? An analysis of US national survey data (NHANES) by Hirode and Wong, published in JAMA in 2020, found a weighted prevalence of 34.7 percent among US adults from 2011 to 2016. Prevalence rose with age, from 19.5 percent among adults 20 to 39 to 48.6 percent among those 60 and older. The NHLBI summarizes the situation as about 1 in 3 US adults. The syndrome is also described as largely preventable.

Insulin resistance, the engine under the hood

Of the five components, insulin resistance is the one that links many of the others. Insulin, released by beta cells in the pancreas after a meal, tells the liver, muscle, and fat to take up glucose and store it. In insulin resistance, those tissues respond weakly to the same signal. (If you want the basics of the hormone first, see insulin and diabetes explained and how the body stores and releases glucose.)

Several processes are proposed to feed insulin resistance, and they probably act together.

1. Ectopic fat. When fat cells reach their storage limit, lipid spills into organs that are not built to hold it, such as the liver and skeletal muscle. Lipid byproducts including diacylglycerol and ceramides can interfere with the insulin signaling pathway inside cells.
2. Inflammatory signals. Cytokines from fat tissue activate enzymes inside cells that tag insulin receptor substrate proteins in the wrong places, which blocks the message from reaching the glucose-uptake machinery.
3. Compensation and fatigue. The pancreas makes more insulin to overcome the resistance. For years that keeps glucose normal. If beta cells can no longer keep up, fasting blood glucose rises, and that is the transition to type 2 diabetes.

A plumbing analogy works here. Picture a lock gate that needs more and more water pressure to open. The pump, the pancreas, compensates by working harder. It manages until the pump wears out, and then the water level (blood glucose) climbs. For the full progression, see type 2 diabetes: the biology behind the epidemic.

Visceral fat and why location matters

Fat under the skin (subcutaneous) and fat packed around the abdominal organs (visceral) behave differently. Visceral fat is more strongly associated with metabolic risk. One popular explanation is the portal hypothesis: visceral fat drains into the portal vein that carries blood directly to the liver, so the liver is exposed to its fatty acids and inflammatory products first. That idea is plausible and widely cited, though it is not the only proposed explanation, and the relative roles of visceral fat, liver fat, and fat in muscle are still being debated.

This is why two people with the same BMI can have different metabolic profiles, and why waist circumference adds information that BMI lacks. A person with more fat stored under the skin and a modest waist often has a better risk profile than a person with the same BMI and more fat around the organs.

Complications that reach beyond blood sugar

Because fat tissue and the liver are connected to nearly every system, the consequences are broad.

• Cardiovascular disease. Metabolic syndrome raises the risk of coronary heart disease, diabetes, and stroke, according to the NHLBI. Over years, high blood pressure, abnormal lipids, and inflammation damage artery walls. See cardiovascular disease and atherosclerosis.
• Fatty liver disease. Excess fat deposits in liver cells and can progress to inflammation and scarring in some people.
• Cancer risk. Excess body weight is associated with higher risk of several cancers. Proposed mechanisms include higher circulating insulin and growth factors and altered sex hormone levels, though the strength varies by cancer type.
• Other conditions. Sleep apnea, joint wear, and reproductive problems also track with excess weight, though in each case the relationship runs in more than one direction.

An important distinction applies here. These are associations backed by mechanisms and large studies, not guarantees for any single person.

Treatment: what the trials show

Treatment has shifted over the past few years. Lifestyle programs remain a foundation, but medicines that act on the brain's appetite circuits now produce larger average weight loss than older drugs. The table gives headline results from major randomized trials. Every row reports a trial average, not a promise for any individual, and the trials differ in design and duration.

Trial or treatment	Key result	Duration and population
STEP 1, semaglutide 2.4 mg weekly (Wilding, NEJM, 2021)	Mean weight change minus 14.9% versus minus 2.4% with placebo; minus 16.9% among those who stayed on treatment	68 weeks; 1,961 adults with obesity or overweight with a comorbidity, without diabetes
SURMOUNT-1, tirzepatide weekly (Jastreboff, NEJM, 2022)	Mean weight change about minus 15.0%, minus 19.5%, and minus 20.9% at 5, 10, and 15 mg versus minus 3.1% with placebo	72 weeks; 2,539 adults
SELECT, semaglutide 2.4 mg weekly (Lincoff, NEJM, 2023)	Major cardiovascular events in 6.5% versus 8.0% with placebo (hazard ratio 0.80); mean weight change minus 9.4% versus minus 0.9% at 104 weeks	Mean follow-up about 40 months; 17,604 adults 45 or older with established cardiovascular disease and overweight or obesity, without diabetes
DiRECT, intensive low-calorie diet program in primary care (Lean, Lancet, 2018)	Diabetes remission at 12 months in 46% versus 4% in the control group	149 participants per group, people with type 2 diabetes of recent onset

Several points are worth reading closely.

GLP-1 and related drugs. GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. Drugs that mimic it, and in tirzepatide's case also mimic a second hormone called GIP, act on appetite regions in the brain and slow stomach emptying. That gives them a different target than older weight-loss drugs. For the mechanism in detail, see how GLP-1 drugs work. In SURMOUNT-1, the 22.5 percent figure sometimes quoted comes from an analysis that assumes people stayed on treatment, while 20.9 percent is the figure for the primary analysis. Reading which analysis a headline uses matters.

Side effects and stopping. In STEP 1, gastrointestinal problems led to treatment discontinuation in 4.5 percent of people on semaglutide versus 0.8 percent on placebo. In SELECT, adverse events led to stopping in 16.6 percent versus 8.2 percent, mostly because of gastrointestinal complications. Trial follow-ups have also reported substantial weight regain after the drug is stopped, which fits the view that obesity is a chronic condition that needs ongoing management. Anyone considering these medicines needs a clinician to weigh benefits, risks, and costs.

Heart outcomes. SELECT matters because it tested hard outcomes, not just weight. It reported about a 20 percent relative reduction in major cardiovascular events in people with existing heart disease. It does not show that the same benefit applies to everyone with obesity.

Surgery. Bariatric operations such as gastric bypass and sleeve gastrectomy remain among the most effective treatments for severe obesity in long-term studies. They change gut hormone signaling and bile acid handling as well as stomach size, which is one reason blood sugar can improve soon after surgery. Specific percentages vary by study and procedure, so a surgeon or obesity specialist is the right source for individual expectations.

Lifestyle and diet. DiRECT showed that an intensive, structured program with a very-low-calorie phase in primary care could put diabetes into remission for nearly half of the participants at one year. The trial authors reported that 24 percent of the intervention group lost 15 kg or more. Follow-up reports found that remission was more likely in those who lost more weight. This supports a point made earlier: in early disease, type 2 diabetes can be reversible, though remission is not a cure, and it can relapse.

Weight stigma is a clinical problem too

Weight stigma, meaning bias and discrimination because of body size, is common in health care and everyday life. Research on stigma reports that people who feel judged may avoid medical visits, and that stress is itself linked to cortisol and appetite. The causal chain is difficult to measure, and studies differ, so the claim here is modest: stigma does not help people lose weight, and it can get in the way of care. A biological framing does not remove personal choices, but it does put them in context.

BMI, the "obesity paradox," and metabolic health

Two observations complicate simple stories. First, in some groups, such as older adults or people with advanced heart or kidney disease, higher BMI has been associated with better survival than a normal BMI. Researchers call this the obesity paradox. Proposed explanations include metabolic reserve during serious illness, the way BMI misses muscle and fat distribution, and bias in who gets studied. It is not generally read as evidence that excess weight is protective.

Second, some people with obesity have normal blood pressure, glucose, and lipids and are described as metabolically healthy. Whether that state is stable over decades is disputed, and many studies suggest a good number of such individuals eventually develop metabolic abnormalities. Both observations point to the same lesson: a single number, whether BMI or weight, cannot capture risk.

Common misunderstandings

"It is just calories in, calories out." Energy balance is true as physics and incomplete as an explanation. It does not explain why appetite and metabolism shift when weight changes, or why food composition alters intake.

"Leptin resistance means leptin is low." Typically the opposite. Levels are high in most people with obesity. The problem is the response, not production.

"Visceral fat and belly fat are the same thing." Not exactly. Belly size includes both subcutaneous and visceral fat. Imaging is needed to separate them, which is why waist circumference is a rough proxy.

"Metabolic syndrome is a diagnosis that explains symptoms." It is a risk marker. Many people with it feel entirely well, which is part of why it goes undetected.

"These drugs are shortcuts." They act on biology that already exists. The trial data show a large average effect, side effects that lead some people to stop, and an expectation of long-term treatment.

"Obesity is the same disease in everyone." It is a shared label for a condition with many causes, which is part of why responses to the same treatment vary widely.

The takeaway

The central insight of the last three decades is that body weight is regulated. Fat tissue reports its size to the brain, circuits in the hypothalamus weigh that report against others, and the system defends a weight range with changes in hunger and energy expenditure. In obesity, the signal gets distorted and the defended range creeps upward, while an environment of easy calories pushes in the same direction.

Metabolic syndrome is what that distortion looks like when it spreads from fat tissue to the liver, muscle, and blood vessels. Seeing the condition as regulation gone wrong explains why willpower alone has a poor record and why drugs that act on appetite circuits work better on average. It also explains why early intervention, whether by lifestyle change, medication, or surgery, can sometimes reverse the damage, and why long-term follow-up matters.

FAQ

Q: Is obesity really a disease or just a risk factor? A: WHO describes obesity as a chronic disease resulting from complex interactions between environmental and psychosocial influences and biological susceptibility. It has an identifiable biology, complications, and treatments. Some people with obesity have no metabolic abnormalities, so the label describes a condition and does not predict health for any one person.

Q: What causes leptin resistance? A: The causes are not fully settled. Proposed mechanisms include inflammation in the hypothalamus, reduced transport of leptin into the brain, and weakened signaling in target neurons. Leptin resistance is mostly defined by what is observed: high leptin levels with persistent hunger and a reduced metabolic response.

Q: How common is metabolic syndrome? A: A 2020 JAMA analysis of US national data found a weighted prevalence of 34.7 percent among adults from 2011 to 2016, and the NHLBI summarizes it as about 1 in 3 US adults. Prevalence rises with age. Figures differ by country and by which diagnostic criteria are used.

Q: Why does weight loss slow down or reverse over time? A: The body responds to weight loss with hormonal and metabolic changes that favor regain, including greater hunger and lower energy expenditure. In the six-year Biggest Loser follow-up, resting metabolic rate stayed well below baseline even after most of the weight had returned, though a small, atypical group limits how widely this can be generalized.

Q: Can type 2 diabetes caused by excess weight go into remission? A: In some people, yes. In the DiRECT trial, 46 percent of participants in an intensive weight-management program had diabetes remission at 12 months, versus 4 percent of controls. Remission is more likely with larger weight loss and a shorter time since diagnosis, and it can relapse, so ongoing monitoring remains important.

Q: How do GLP-1 drugs lead to weight loss? A: They mimic gut hormones that act on appetite regions of the brain and slow stomach emptying, which reduces hunger and increases fullness. In STEP 1, semaglutide produced an average 14.9 percent weight loss over 68 weeks, and in SURMOUNT-1, tirzepatide produced up to 20.9 percent over 72 weeks. They carry side effects, and decisions about use belong with a clinician.

Q: Does where fat is stored really matter? A: Yes. Visceral fat around the abdominal organs is more strongly associated with insulin resistance, fatty liver, and cardiovascular risk than subcutaneous fat. Waist circumference gives a rough measure of this, which is one reason it appears in the diagnostic criteria for metabolic syndrome.

Sources

• World Health Organization. Obesity and overweight fact sheet, updated October 7, 2026. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
• National Heart, Lung, and Blood Institute. Metabolic Syndrome. https://www.nhlbi.nih.gov/health/metabolic-syndrome
• American College of Cardiology. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT), trial summary. https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select
• Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
• Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023.
• Lean MEJ et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). The Lancet. 2018.
• Hall KD et al. Ultra-processed diets cause excess calorie intake and weight gain. Cell Metabolism. 2019.
• Fothergill E et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016.
• Turnbaugh PJ et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006.
• Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA. 2020;323(24):2526-2528. doi:10.1001/jama.2020.4501
• Zhang Y et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994. Farooqi IS et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. New England Journal of Medicine. 1999.

---

Read next:

• Type 2 Diabetes: The Biology Behind the Epidemic
• Cardiovascular Disease & Atherosclerosis: The Biology
• Insulin and Diabetes Explained: Biology, Types, Treatment